Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care
Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Masimo Corporation - MASI
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Masimo activist Politan presents 'last chance' for shareholders to force change at med-tech company
Masimo activist Politan laid out its renewed case for change in a push to win two more board seats at the medical device company. Politan seeks to oust CEO Joe Kiani from the board and says the company can deliver $10 billion in shareholder value with the right governance and oversight.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Masimo Corporation - MASI
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Masimo Corporation - MASI
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
Masimo's (MASI) R&D activities raise optimism about the stock.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Masimo Corporation - MASI
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Masimo's (MASI) New Offering to Serve Personalized Audio Market
Masimo's (MASI) new product offering is expected to enable it to expand its footprint in the personalized hearables market by offering personalized listening experiences.
Charles Schwab Investment Management Inc. Purchases 20,519 Shares of Masimo Co. (NASDAQ:MASI)
Charles Schwab Investment Management Inc. boosted its position in shares of Masimo Co. (NASDAQ:MASI – Free Report) by 5.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 368,041 shares of the medical equipment provider’s stock after buying an additional 20,519 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.70% of Masimo worth $43,138,000 as of its most recent SEC filing. Several other institutional investors have also added to or reduced their stakes in the company. Duality Advisers LP bought a new stake in Masimo in the third quarter worth $1,066,000. NBC Securities Inc. bought a new stake in shares of Masimo in the 3rd quarter worth about $34,000. Assenagon Asset Management S.A. purchased a new stake in shares of Masimo during the 3rd quarter valued at about $2,279,000. Arizona State Retirement System lifted its holdings in shares of Masimo by 4.7% in the 3rd quarter. Arizona State Retirement System now owns 12,773 shares of the medical equipment provider’s stock valued at $1,120,000 after acquiring an additional 571 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in Masimo in the third quarter worth about $1,449,000. Hedge funds and other institutional investors own 85.96% of the company’s stock. Insider Buying and Selling In other Masimo news, Director Craig B. Reynolds sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $136.17, for a total value of $5,446,800.00. Following the completion of the sale, the director now directly owns 7,406 shares in the company, valued at $1,008,475.02. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 9.70% of the stock is currently owned by company insiders. Wall Street Analyst Weigh In MASI has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, May 8th. Jefferies Financial Group restated a “hold” rating and issued a $121.00 price target (up from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. BTIG Research increased their price objective on shares of Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. StockNews.com upgraded Masimo from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Finally, Wells Fargo & Company upgraded Masimo from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $117.00 to $160.00 in a report on Monday, March 25th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $138.71. Read Our Latest Research Report on Masimo Masimo Stock Up 2.9 % Shares of NASDAQ MASI opened at $124.10 on Monday. The stock has a market capitalization of $6.59 billion, a PE ratio of 84.42 and a beta of 0.99. The company has a current ratio of 2.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.62. Masimo Co. has a 12-month low of $75.22 and a 12-month high of $169.58. The stock’s fifty day simple moving average is $134.76 and its two-hundred day simple moving average is $121.79. Masimo (NASDAQ:MASI – Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.06. The company had revenue of $492.80 million for the quarter, compared to the consensus estimate of $487.70 million. Masimo had a return on equity of 13.26% and a net margin of 4.01%. The firm’s revenue for the quarter was down 12.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.87 earnings per share. As a group, analysts expect that Masimo Co. will post 3.64 EPS for the current fiscal year. About Masimo (Free Report) Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. Read More Five stocks we like better than Masimo How to Buy Cheap Stocks Step by Step MarketBeat Week in Review – 5/13 – 5/17 Are Penny Stocks a Good Fit for Your Portfolio? Take-Two Interactive Software Offers 2nd Chance for Investors Best Stocks Under $10.00 Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
